ID: ALA216298

Max Phase: Preclinical

Molecular Formula: C16H22O3

Molecular Weight: 262.35

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  C[C@H]1CC[C@@H](O)C(C)(C)[C@@]12Cc1cc(O)ccc1O2

Standard InChI:  InChI=1S/C16H22O3/c1-10-4-7-14(18)15(2,3)16(10)9-11-8-12(17)5-6-13(11)19-16/h5-6,8,10,14,17-18H,4,7,9H2,1-3H3/t10-,14+,16+/m0/s1

Standard InChI Key:  LCCNGMPSHBOPBJ-DRZCJDIDSA-N

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 262.35Molecular Weight (Monoisotopic): 262.1569AlogP: 2.88#Rotatable Bonds: 0
Polar Surface Area: 49.69Molecular Species: NEUTRALHBA: 3HBD: 2
#RO5 Violations: 0HBA (Lipinski): 3HBD (Lipinski): 2#RO5 Violations (Lipinski): 0
CX Acidic pKa: 9.96CX Basic pKa: CX LogP: 3.15CX LogD: 3.15
Aromatic Rings: 1Heavy Atoms: 19QED Weighted: 0.76Np Likeness Score: 2.66

References

1. Useglio M, Castellano PM, Operto MA, Torres R, Kaufman TS..  (2006)  Synthesis of 3H-spiro[benzofuran-2,1'-cyclohexane] derivatives from naturally occurring filifolinol and their classical complement pathway inhibitory activity.,  16  (19): [PMID:16875818] [10.1016/j.bmcl.2006.07.029]

Source